ClinicalTrials.gg
RecruitingNCT04050566MBCUpdated Sep 1, 2021

Malaria Birth Cohort (MBC) in Agogo, Ghana

An observational study in Malaria, sponsored by Bernhard Nocht Institute for Tropical Medicine. Recruiting at 1 site in Ghana. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-01.

Sponsored by Bernhard Nocht Institute for Tropical Medicine · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2019; still recruiting 7 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,800
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Malaria with a site in Ghana — 5 open to participants now, 6 under way, none of them phase 3. Malaria · Ghana.

Planned enrollment
6th of 11
1,800 · median 1,800
Started
2019
with 2 others
Observational
11 of 59
2 open now
Registered
50th of 59
by date
Lead sponsor
2 of 59
Bernhard Nocht Institute for Tropical Medicine

Among the 59 studies in Malaria with a site in Ghana, this one is the 6th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2019, is one of 11 observational ones, and was the 50th registered.

Malaria

1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

5 of the 59 studies in Malaria with a site in Ghana are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Ghana have not opened yet or have stopped. Only those recruiting at a site in Ghana →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Malaria with a site in Ghana, or all of them as a file.
02

Study summary

Malaria is a major health threat worldwide with an estimated 229 million cases and 409,000 deaths in 2019 (WHO, World Malaria Report 2019). Vulnerable are young children and pregnant women. The study aims to investigate immunity development against malaria with regard to parasite, human, and socioeconomic factors and possible correlations with pathology or protection in a prospective birth cohort.

Read the detailed description

Malaria during pregnancy poses substantial risks for the mother and her foetus. Due to the risk of malaria during early childhood, the study addresses the high malaria morbidity and mortality in young children. Though recognised as a public health issue, it has still not been well understood how clinical immunity against malaria parasites develops, which parasite and host factors play a role in infection susceptibility, and why some infections proceed to develop severe complications while others resolve after a mild disease.

In order to identify interactions between parasite and host, a longitudinal study is performed starting with the recruitment of pregnant women. The study is conducted in Agogo in Ghana, an area with high malaria endemicity. The study design allows to analyse the neonatal immune status at birth, after potential in-utero exposure, and follows the development of immunity over the first 36 months of life. The current paradigm is that time points and frequency of infection as well as the type of variant surface antigen expressed have an impact on the cellular and humoral immune response to malaria, the development of clinical immunity, as well as the risk for future complications.

Starting point of the study is the antenatal care visit of mothers at Agogo Presbyterian Hospital (APH) during pregnancy. During recruitment, the mother will be asked to read and sign an informed consent form approved by the local ethical committee. After consent has been obtained from the mother, biological samples are taken, and a case report form is filled. An identification card with a unique code number is handed out. The first follow-up visit occurs at the birth of the child. At this time point, samples are taken from the mothers and the child. Mothers/primary caregivers are invited to observe the EPI visits offered at their nearest health post for further follow-ups. In the first year after birth, the EPI schedule includes visits at six weeks, ten weeks, 14 weeks, six months, and nine months. During these visits, questionnaires are completed and stool samples are taken. In the first six weeks after birth, the household is visited to complete a household questionnaire including housing characteristics and household assets. Additionally, a women's questionnaire is administered, which collects demographic and socioeconomic background characteristics as well as health and related behavioural data. At 12, 18, 24, and 36 months after birth, mothers/primary caregivers are encouraged to bring their children to the study hospital (APH) for a medical check-up. For the period of 36 months after birth, mothers/primary caregivers are strongly encouraged to visit the study hospital (APH) every time the child experiences a febrile illness or a history of fever in the last week during the observation period.

03

Conditions studied

  • Malaria

Browse trials for

Keywords

  • Malaria
  • Immunity development
  • Plasmodium diversity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Pregnant women visiting Agogo Presbyterian Hospital (APH) for their antenatal care visit and the newborn children born to these mothers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Catchment area of the EPI (Expanded Program of Immunization) centres with good accessibility to Agogo Prespyterian Hospital (APH)
  • Willingness and able to give for herself and her child

Exclusion criteria

Exclusion Criteria:

  • Maternal age below 18 years
  • Positive status of mother
  • Refusal or withdrawal of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Mothers

    900 mothers recruited during pregnancy

  • Children

    900 children born to the recruited mothers

06

What researchers measure

Primary outcomes

  1. Malaria episodes

    Frequency and severity of malaria episodes as identified by microscopy, PCR, and clinical criteria.

    Time frame: First 36 months of life

Secondary outcomes

  1. T cell repertoire

    T cell repertoire as measured by FACS analysis

    Time frame: First 36 months of life

07

Study locations

1 of 1 sites recruiting
  • Agogo Presbyterian Hospital
    Agogo, Ghana
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Apr 2025, 72 months after the start.

Of 85 non-industry observational studies under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 72 months is above that.

Counting every sponsor, half of 93 studies reached it within 24 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2019
First posted
Aug 8, 2019
StartActual
Apr 8, 2019
Primary completionEst.
Apr 2025
CompletionEst.
Apr 2025
Last update
Sep 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04050566
Lead sponsor
Bernhard Nocht Institute for Tropical Medicine
Collaborators
Kwame Nkrumah University of Science and Technology, Kumasi Centre for Collaborative Research (KCCR), Heidelberg University, KEMRI-Wellcome Trust Collaborative Research Program, Agogo Presbyterian Hospital
Responsible party
Dr. Jürgen May (Professor, Department Head, Bernhard Nocht Institute for Tropical Medicine) — Principal investigator
First posted
Aug 8, 2019
Start date
Apr 8, 2019
Primary completion
Apr 2025 (estimated)
Completion
Apr 2025 (estimated)
Last update
Sep 1, 2021

Study contacts

Eva Mertens, PhD
Contact
mertens@bnitm.de
+49 40 42818 ext. 243
Nicole Struck, PhD
Contact
struck@bnitm.de
+49 40 42818 ext. 639
Jürgen May, Prof
study director · Bernhard Nocht Institute for Tropical Medicine
John H Amuasi, Dr
study director · Kwame Nkrumah University of Science & Technology (KNUST)
Eva Mertens, PhD
principal investigator · Bernhard Nocht Institute for Tropical Medicine
Nicole Struck, PhD
principal investigator · Bernhard Nocht Institute for Tropical Medicine
Oumou Maiga-Ascofaré, PhD
principal investigator · Kumasi Centre for Collaborative Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion